Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis NRT gum OTC

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health plans by the end of 2007 to make available nationwide its 2 mg and 4 mg Thrive (nicotine polacrilex) nicotine-replacement therapy gum, following FDA's ANDA approval of the product for over-the-counter sales, the firm says June 21. The Parsippany, N.J.-based division of Novartis says the mint-flavored gum delivers nicotine to the bloodstream in "low, controlled levels" to help reduce cravings and other symptoms of smoking cessation. The 2 mg product is designed for users who smoke fewer than 25 cigarettes a day and the 4 mg version is for people with a daily habit of at least 25 cigarettes. The firm says the 12-week program printed on the user's guide in Thrive packages and available on a CD will help consumers reduce their nicotine levels and quit smoking. Novartis also will operate a toll-free phone service to counsel consumers, citing the American Legacy Foundation's guidance to combine nicotine replacement therapy with counseling and social support as part of a comprehensive plan for quitting...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS100638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel